Skip to main content
. 2023 Sep 26;40(12):5536–5546. doi: 10.1007/s12325-023-02668-x

Fig. 1.

Fig. 1

Rate of decline in FVC (mL/year) over 52 weeks of the INBUILD trial in subgroups by baseline characteristics

HHS Vulnerability Disclosure